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ABSTRACT: 13C NMR has many advantages for a metabolomics study, including a large spectral dispersion, narrow singlets at
natural abundance, and a direct measure of the backbone structures of metabolites. However, it has not had widespread use
because of its relatively low sensitivity compounded by low natural abundance. Here we demonstrate the utility of high-quality
13C NMR spectra obtained using a custom 13C-optimized probe on metabolomic mixtures. A workflow was developed to use
statistical correlations between replicate 1D 13C and 1H spectra, leading to composite spin systems that can be used to search
publicly available databases for compound identification. This was developed using synthetic mixtures and then applied to two
biological samples, Drosophila melanogaster extracts and mouse serum. Using the synthetic mixtures we were able to obtain useful
13C−13C statistical correlations from metabolites with as little as 60 nmol of material. The lower limit of 13C NMR detection
under our experimental conditions is approximately 40 nmol, slightly lower than the requirement for statistical analysis. The 13C
and 1H data together led to 15 matches in the database compared to just 7 using 1H alone, and the 13C correlated peak lists had
far fewer false positives than the 1H generated lists. In addition, the 13C 1D data provided improved metabolite identification and
separation of biologically distinct groups using multivariate statistical analysis in the D. melanogaster extracts and mouse serum.
NMR-based metabolomics is most commonly done with1H detection. Although 13C is often used for compound
identification, it is usually recorded indirectly using experiments
such as HSQC (heteronuclear single quantum correlation),
HMBC (heteronuclear multiple bond correlation), or their
variants, all of which employ 1H detection. These indirect
methods are powerful but suffer from the unreliable detection
of quaternary carbons and correlations that are sometimes
difficult to assign, especially with HMBC. Indirect methods also
suffer from limited digital resolution along the large 13C
chemical shift dimension. Despite its widespread use, 1H NMR
metabolomics studies of mixtures are often complicated by
resonance overlap from a relatively narrow 10 ppm diamagnetic
chemical shift range. This overlap is exacerbated by 1H
homonuclear coupling, which creates multiplets that can
complicate analysis, although 2D J-resolved experiments can
improve that problem. Many 1H chemical shifts are sensitive to
pH, temperature, or salts, complicating spectral alignment and
database matching. In addition, water reduction can obscure
nearby resonances and distort baselines, which can make 1H-
based metabolomics analyses difficult.
13C NMR offers many advantages for a metabolomics study,
either alone or as a complement to 1H NMR: (1) 13C spectral
windows are typically 200 ppm, providing much greater
chemical shift dispersion than 1H; (2) at natural abundance,
13C resonances of small metabolites are narrow singlets (with
1H decoupling) resulting in less spectral overlap; (3) biogenic
metabolites predominantly contain a carbon backbone, and 13C
NMR can detect this directly, including quaternary carbons.
These advantages raise the possibility of easier identification of
metabolites and better separation between experimental groups
using multivariate analyses because of better spectral dispersion.
The major obstacle to 13C NMR metabolomics compared to
1H is low sensitivity due to low natural abundance of 13C
(∼1.1%) combined with a decreased gyromagnetic ratio γ (one-
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quarter of that of 1H). Because the energy of an NMR
resonance transition is proportional to γ3, 13C has an intrinsic
sensitivity decrease of nearly 64 (43) when compared to 1H.
Though solutions such as isotopic labeling exist,1−5 they can be
expensive and are often restricted to targeted metabolomics.
Untargeted studies with 13C labeling are especially challenging
for organisms that cannot be cultured. In addition, isotopic 13C
labeling reintroduces the problem of homonuclear couplings,
which complicate 13C spectra. The other solution is to improve
13C sensitivity, either through higher magnetic field strengths
that improve the Boltzmann polarization,6 a variety of
hyperpolarization techniques,7,8 or improved detection with
an optimized probe.9 We have designed and built a 1.5 mm
high-temperature superconducting (HTS) 13C optimized
probe. This probe has a minimal sample volume of 35 μL
and over 2× greater 13C mass sensitivity than any commercially
available 13C-optimized cryogenic probe, which translates to
well over 4× less measurement time for the same sample and
same signal-to-noise ratio.9 This new technology makes 13C
metabolomics at natural abundance technically feasible.
In the present study we show that 1D 13C data enhance
metabolite identification and facilitate better separation of
groups for comparison using multivariate statistical analysis
when compared to 1D 1H data alone. We analyzed the 13C and
1H 1D data sets with 13C−13C statistical total correlation
spectroscopy (STOCSY)10,11 and 13C−1H statistical hetero-
spectroscopy (SHY)12−14 to compile correlated peak lists that
were then used in database searches for compound
identification. We developed and validated the workflow
using synthetic mixtures of 20 common metabolites, defined
the limits of detection using current technology, and compared
the peak lists generated using both 13C and 1H data to those
generated using 1H data alone. We then applied our workflow
to comparisons of two types of biological mixtures: extracts of
cold hardy and cold susceptible Drosophila melanogaster flies, to
demonstrate the superior performance of 1D 13C compared to
1D 1H in multivariate statistical analysis, and mouse serum
taken from control and the Duchenne muscular dystrophy
mouse model, mdx,15 to demonstrate the power of 13C
metabolomics to not only aid in metabolite identification but
also to prevent misidentification.
■ EXPERIMENTAL METHODS
Synthetic Mixtures. Synthetic mixtures with known
metabolite compositions were constructed to test the limits
of detection of the probe and our ability to correctly identify
known compounds. Two groups of mixtures (groups A and B,
five replicates each) were each made using 20 common
synthetic metabolites ranging in concentration from 1 to 5 mM
(Table 1). The first 10 metabolites were at equal concen-
trations in all mixtures in both groups, and the remaining 10
metabolites differed between groups with half higher in group A
and half higher in group B (Table 1). Rather than prepare a
uniform batch to eliminate concentration differences between
samples, each metabolite was pipetted individually into each
mixture. This was to increase the random mixture-to-mixture
variation of individual metabolites both within and between
groups due to pipetting errors. This random variation between
samples allowed us to develop and validate the statistical
methods (i.e., STOCSY) used in this study. Variation was not
controlled in this experiment and is assumed to be random.
Each sample was brought to 50 μL using 99% D2O (Cambridge
Isotope Laboratories), of which 40 μL was pipetted into a 1.5
mm (OD) NMR tube (Norell).
Drosophila melanogaster Tissue Extracts. Flies were
selected in the laboratory for high (hardy) or low (susceptible)
cold hardiness (Williams et al., unpublished results). Flies were
lyophilized and weighed prior to metabolite extraction. Polar-
phase metabolites were extracted from homogenized fly tissue
using an aqueous-optimized metabolite extraction protocol.16
Twenty replicates of each genetic line (cold hardy and cold
tolerant) were collected with 40 flies per replicate. Polar phase
extracted metabolites were dried and reconstituted in 40 μL of
99% D2O (Cambridge Isotope Laboratories) and pipetted into
1.5 mm NMR tubes (Norell).
Mouse Serum. The Duchenne muscular dystrophy (DMD)
mouse model, mdx, has previously been investigated with
metabolomics using tissue extracts, but to our knowledge,
serum has not been investigated using both 1H and 13C. One
technical difficulty is the small quantity of sample available for
NMR in mouse serum studies. Mouse measurements were
performed on serum from 6 month old C57/B10 control (n =
6) and mdx (n = 8) mice. Two hundred microliters of blood
was collected by submandibular puncture, clotted, and
centrifuged to extract serum. The mice were then humanely
euthanized under 2% isofluorane anesthesia according to
approved IACUC protocols. Once the serum was separated
from the red blood cells, it was flash frozen in liquid nitrogen
Table 1. Composition and Summary Results for the
Synthetic Metabolite Mixtures Used in This Study
target
concentrationa per
group (mM)
database IDsb/false
correlationsc
metabolite A B 13Cd 1He
L-alanine 1.5 1.5 Y/1 N
D-trehalose 1.0 1.0 N N
L-phenylalanine 1.0 1.0 N N
malate 2.5 2.5 N N
L-aspartic acid 3.0 3.0 Y/0 N
L-asparagine 2.5 2.5 Y/0 N
L-threonine 3.5 3.5 Y/0 N
D-fructose 1.5 1.5 N N
L-glutamine 2.0 2.0 N N
L-valine 3.0 3.0 Y/1 Y/0
L-methionine (Met) 2.0 1.0 Y/0 N
L-proline (Pro) 3.0 1.5 Y/0 N
L-glutamate (Glu) 5.0 2.0 Y/2 Y/8
D-glucose (Glc) 2.5 1.5 Y/0 Y/9
L-isoleucine (Ile) 3.0 1.0 Y/0 Y/0
L-arginine (Arg) 2.0 3.0 Y/2 Y/0
nicotinamide (NAM) 2.0 3.5 Y/0 N
L-carnitine (Car) 1.0 2.0 Y/0 N
L-lysine (Lys) 1.0 3.5 Y/0 Y/9
L-tryptophan (Trp) 1.5 2.5 Y/1 Y/3
compds identified in BMRB 15/20 7/20
aCompounds were transferred to NMR tubes individually to simulate
typical between-sample variation, as described in the Methods. bA
database ID is yes (“Y”) when a COLMAR query search of the BMRB
returns the known compound in the top 10 matches. Otherwise it is
no (“N”). cFalse correlations are peaks that were in the peak list
generated from the correlation maps but not part of the identified
compound. dResults obtained using 13C and the entire workflow
outlined in this paper. eResults obtained by only using 1H−1H
STOCSY data and no 13C data.
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and stored at −80 °C. Approximately 100 μL of serum was
lyophilized and resuspended in 40 μL of 99% D2O and
transferred into 1.5 mm NMR tubes (Norell).
NMR Data Collection and Processing. One-dimensional
1H and 13C spectra were collected on an Agilent VNMRS-600
spectrometer using a custom 1.5 mm 13C high-temperature
superconducting (HTS) probe.9 Synthetic mixture and fly
extract 1H 1D data were collected in ∼2.5 min using a simple
pulse sequence with presaturation of residual water, a spectral
width of 12 ppm (7183.9 Hz), an observe frequency of 599.68
MHz, a 2.0 s relaxation delay, a 45° pulse, and 2.3 s acquisition
time. Mouse serum 1H data were collected in 18 min using a
Carr−Purcell−Meiboom−Gill (CPMG) sequence, to remove
the protein signal contribution resulting in a flat baseline.
Mouse data were recorded with a spectral width of 16 ppm
(9615.4 Hz), a 2.0 s relax delay, a 90° initial pulse, a train of 124
180° pulses with a 1 ms interpulse delay, and a 2.0 s acquisition
time. All 13C spectra were collected under conditions that favor
nuclei with short T1 relaxation times to maximize overall
sensitivity and minimize measurement time: a 60° pulse with a
0.1 s relaxation delay and a 0.8 s acquisition time. The total
time for each 13C spectrum was ∼2 h, with a 212 ppm (32051.3
Hz) spectral window and a carrier frequency of 98.0 ppm at a
frequency of 150.79 MHz. The mouse serum 13C CPMG
sequence used a 90° excitation pulse followed by a train of 18
180° pulses with a 1 ms interpulse delay. All 13C spectra were
recorded using continuous 1H decoupling at 599.68 MHz with
a power of 37 dB using WALTZ-16. All NMR spectra were
processed in NMRPipe.17 All 1H spectra were processed using a
cosine-squared window function, zero-filled 2×, Fourier-
transformed, and baseline-corrected. 13C spectra were pro-
cessed using an exponential window function with a 2 Hz line
broadening, zero-filled 2×, Fourier-transformed, and baseline-
corrected. The synthetic mixture and fly extract 1H spectra were
referenced to TSP (0.0 ppm); mouse serum 1H spectra were
referenced to the lactate peak at 4.1 ppm, because TSP binds to
proteins. 13C spectra were referenced to the anomeric carbon
glucose peak at 98.64 ppm.
Fourier-transformed and referenced spectra were imported
into an in-house MATLAB Metabolomics Toolbox that has
been developed in our laboratory. This Toolbox is a collection
of MATLAB scripts that includes various analytical tools for the
alignment, normalization, scaling, and multivariate analysis of
complex data. The Metabolomics Toolbox has several options
for alignment, but we found that the star alignment algorithm
where an individual spectrum is chosen as a “star” to which all
other spectra are aligned,18 gave the best results in this study.
For the statistical correlations, we binned the 1H spectra using
an open source optimized bucketing algorithm described by
Sousa et al.19 13C spectra were peak picked by setting all
resonances below 2× the standard deviation of all spectra to
zero, finding local maxima, and then merging peaks within 0.2
ppm together. Optimal normalization and scaling methods
were specific for each data set. 13C and 1H spectra of the
synthetic mixtures and mice serum were normalized using
probabilistic quotient normalization20 (PQN) and scaled using
pareto scaling.21 PQN can be used with NMR spectra in the
absence of a reliable internal standard. Pareto scaling is similar
to autoscaling except that it keeps more to the original data set
and is less susceptible to noise. This prevents the high-intensity
peaks from dominating our models. 1H fly spectra were
normalized to TSP (an internal standard) and scaled using
range scaling.21 Range scaling is also similar to autoscaling by
allowing all metabolites to become equally important. Unlike
autoscaling, it uses the biological range as a scaling factor. This
is useful for exploratory analysis as in our experiments and
multivariate statistical analysis were performed with no previous
knowledge of the contents of our fly mixtures. Range scaling
has been shown to give biologically sensible results.21 Principal
component analysis (PCA) was conducted on the 1D 1H and
13C data sets of the synthetic mixtures and fly samples. Partial
least-squares-discriminant analysis (PLS-DA) was conducted
on the 1D 1H and 13C data sets of the both the fly samples and
Figure 1. Overview of approach to 1H and 13C NMR statistical analysis of synthetic mixtures. The 1D 13C (A) and 1H (B) spectra were processed,
aligned, normalized, and scaled. Compounds below 1.5 mM (indicated by * in (A)) showed no significant correlations. 13C−13C STOCSY (C) and
13C−1H SHY (D) maps were then made from all of the data in (A) and (B). An expansion of the aromatic region of the 13C−13C STOCSY (C) is
shown in H. 13C−13C STOCSY traces of resonances (i.e., driver peak (↓) at 114.8 ppm in (E)) were used to generate peak lists as described in the
text. Negatively correlated peaks were removed (F), and positively correlated peaks with significant correlations as described in Methods (G) were
used as inputs for COLMAR query searches, which for example, found tryptophan (Trp). Tryptophan 1D 1H and 13C reference spectra from the
BMRB (black) are overlaid on both correlation matrices (C and D) and the expansion region in (H).
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mouse serum. All NMR raw data, processing scripts, and
MATLAB code were deposited in the Metabolomics Work-
bench database (http://www.metabolomicsworkbench.org/)
supported by the NIH Common Fund.
Data Analysis. Our workflow consisted of computing
statistical correlations to compile peak lists, followed by
database searching to identify metabolites (Figure 1). All of
the steps described below were implemented in an in-house
MATLAB Metabolomics Toolbox22 that was used to analyze all
the data sets.
1. Statistical Correlations. We calculated 2D statistical
correlation maps for 13C−13C and 1H−1H homonuclear
(STOCSY:10,11 Figure 1C) and 1H−13C heteronuclear spectra
(SHY:12−14 Figure 1D). In 1D versions of STOCSY and SHY,
correlations and covariance are determined for a specific
“driver” peak of interest. In the 2D implementation used here,
each peak serves as a driver for all other resonances in the
spectra, as shown in panels C and D in Figure 1.
2. Generation of Peak Lists. The STOCSY and SHY maps
were analyzed by an in-house script written in MATLAB
according to the following steps. We first systematically
evaluated all 13C Pearson correlations and covariances from
the STOCSY and removed any that were not greater than 0.
Thus, all peak lists were constructed from the positive 13C 2D
correlation map, as shown in Figure 1C. We systematically
examined all 13C frequencies along the vertical STOCSY axis
now considered “driver peaks”for every 13C and 1H
resonance along the horizontal axes of the STOCSY and
SHY, respectively (Figure 1E). A starting point for peak lists for
database searching was generated by compiling list of peaks that
covary with the driver peak by ±half the covariance of the
driver peak with itself. This was done to eliminate resonances
that have a high correlation but a low covariance with the driver
peak. In addition, if the significance (q) of a correlation was less
than 0.05 after FDR correction,23 that peak was removed to
further eliminate resonances that are unlikely to be part of the
same molecule (Figure 1F). The remaining peaks (Figure 1G)
had both significantly high correlation and a strong covariance
with the driver peak. Peak lists from all driver peaks were
compared, and those sharing more than three peaks (both 1H
and 13C) were combined and classified as part of the same
metabolite. We found that lists sharing at least three peaks
improved our metabolite coverage. Fewer shared peaks resulted
in fewer but very large peak lists, and more shared peaks (>3)
essentially excludes compounds with fewer carbons.
The 1H−1H STOCSY results (Supporting Information
Figure S1) were not as useful as the 13C−13C STOCSYs, but
we used these with the synthetic mixture to compare the results
with 13C to traditional approaches with just 1H.
3. Database Searching. At this stage in the analysis, the
peak lists from step 2 could be analyzed several ways including
de novo compound identification using chemical knowledge or,
for known compounds, matched to a database. We chose to use
the COLMAR query24 search engine and the BMRB
database,25 because the BMRB has a large number of
metabolites with assigned 13C spectra. However, any search
protocol and database with both 1H and 13C NMR data could
be used for this step. We note that our database searches in this
study were sequential; namely, we first searched the 13C data
and then searched for 1H data. It would be advantageous in the
future to simultaneously search using all the data. Like all
database searches, several possible matches for each query were
returned, and the final step in our analysis was manual
inspection of BMRB spectra overlaid onto our primary data and
covariance maps for final identification.
■ RESULTS AND DISCUSSION
The goal of this paper was to determine the extent to which 1D
13C NMR can significantly enhance an untargeted metab-
olomics study. The specific algorithmsSTOCSY, SHY,
COLMAR query, and PCA or PLS-DAwere all known and
used with little or no modification but were combined into a
workflow that incorporates the 13C data. We used three
different test cases to evaluate the workflow and approach. To
develop and validate the method, we first used a simple
synthetic mixture of known compounds. This allowed us to
optimize parameters and define the steps of the overall
workflow, as well as allowing us to estimate a lower practical
limit for the amount of material required with current
technology. In order to demonstrate the robustness of this
approach, we applied the workflow to two very different
biological systems, comparing genetically distinct fruit fly lines
with different phenotypic responses to cold and comparing
control mice to those with a known mutation in a gene that
causes muscular dystrophy. The fly data provided an example of
several relatively abundant metabolites that change between
groups, and similar animals have recently been studied using
traditional 1H-based NMR methods, allowing for some
comparisons. The mouse serum data validates that this
technique can be used when only very limited quantities of
starting material are available and shows the value of 13C
measurements to confirm or reject assignments from 1H data
alone.
Workflow Development. We collected and analyzed 1D
13C (Figure 1A) and 1H (Figure 1B) spectra of two groups of
synthetic mixtures to determine the limit of detection for this
method and to test our ability to identify metabolites that we
knew were in the samples. The concentration ranges of
metabolites in these mixes were between about 1 and 5 mM;
thus, the total quantity of compounds in each experiment
ranged from 40 to 200 nmol. The metabolites at the lower
concentrations (indicated with an asterisk* in Figure 1A) were
detectable, but only with relatively low S/N. However, we were
unable to obtain 13C correlations for the resonances with the
lowest S/N and were only able to obtain reliable correlations
from compounds at or above about 1.5 mM. Thus, we conclude
that 60 nmol is the lower limit of material that works for this
workflow with the current 13C probe, measurement time, and
other NMR parameters. Several ideas to improve this overall
sensitivity are given below.
The overall workflow is illustrated in Figure 1 with the
identification of tryptophan (Trp) in the synthetic mixtures.
The 13C−13C STOCSY and 1H−13C SHY maps were used to
generate peak lists, as described above. One of the correlated
peak lists had a good match to Trp, following COLMAR query
of the BMRB database. The 1D BMRB reference spectra of Trp
are shown in black on the axes of plots in Figure 1 to illustrate
how the statistical correlations were used to match the
database. A closer look at the 13C−13C STOCSY region
between 109.5 and 141.5 ppm showed the strong correlations
between the aromatic tryptophan peaks (red cross-peaks). The
trace through the 13C−13C STOCSY at one of the aromatic Trp
resonances (114.8 ppm) illustrates the correlations with other
Trp peaks (Figure 1E).
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To evaluate the extent to which 13C data improved our
identification of compounds, we compared results using the
entire workflow outlined in Figure 1 with results that just used
1H−1H STOCSY (Supporting Information Figure S1). Using
all the data (13C and 1H), our workflow returned 36 peak lists
but using the 1H data alone returned only 26 peak lists. It must
be noted that a peak list is defined as the set of correlated peaks
that pass a given information-quality threshold, as described
above in Methods. Peak lists can be fragments of molecules, so
it is not surprising to have a greater number of peak lists than
detected metabolites in the sample. When we searched the
appropriate BMRB database using COLMAR query (i.e., 13C or
1H), using all of the data we found 15 of the correct
compounds in the list of the top 10 hits from the query, but
using just the 1H data we only found 7 of the correct matches
(Table 1). Because the 1H and 13C data were collected from the
same samples and the 1H data had better overall signal-to-noise,
we believe that the major factor underlying the better
performance of the 13C data for compound identification was
that the 13C workflow generated fewer false correlations
defined as a peak in the generated peak list that is not in the
database-matched molecule. In the 1H−1H STOCSY 60% of
the peaks were falsely correlated, but the 13C−13C STOCSY
had only 20% false correlations, as indicated in columns 4 and 5
of Table 1. This large difference in the false correlations results
from the improved resolution in the 13C 1D data. PCA
performed on both 1D 13C (Supporting Information Figure
S2A) and 1H (Supporting Information Figure S2B) data sets
gave predictably good separation considering these were
artificially made groups. However, it can also be seen that the
loadings from the 13C PCA are much better resolved than those
from the 1H PCA (Supporting Information Figure S2). This is
demonstrated more clearly below in the fly data. In general, for
the synthetic test data set, we found that the 13C data were
much more useful than 1H in generating comprehensive peak
lists leading to metabolite identification. In most instances, the
peaks generated from 13C data alone were enough to
successfully match metabolites in the database, and the 1H
data were reserved primarily for verification of results.
13C NMR Data Yields Improved Group Discrimination.
To test our workflow on samples from a biological system, we
utilized two isogenic lines of D. melanogaster, one hardy and
one susceptible to cold exposure. D. melanogaster is a model
organism and the subject of many NMR-based metabolomics
Figure 2. Identification of D. melanogaster metabolites using 1D 13C (A) and 1H NMR (B) data. 13C−13C STOCSY (E) and 2D 13C−1H SHY (F)
correlation maps were generated as described in the text. Slices at 31.69 ppm from the 13C−13C STOCSY (B) and 13C−1H SHY (D) show the
correlations and covariances with that resonance, which yielded proline in a database search. Proline spectra from the BMRB (black lines in (C) and
(D)) are overlaid onto the 1D 13C STOCSY and 13C−1H SHY to confirm identity.
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studies,26−28 making it desirable to optimize the performance of
NMR-based metabolomics for this species. The lines used here
originated from the same population as the Drosophila Genetic
Reference Panel29 but were selected for either rapid (hardy) or
slow (susceptible) recovery from a cold-induced coma (a
common metric of cold tolerance in insects and other
ectotherms). We used these strains because they have a well-
annotated metabolome as well as robust and stable differences
in the metabolome based on previous 1H NMR measurements
(Williams et al., unpublished results), against which we can
evaluate the power of 13C NMR to identify (A) NMR-visible
metabolites and (B) metabolites that discriminate the lines (i.e.,
a biomarker approach). All data were independently analyzed
and subsequently cross-checked with the previously annotated
1D and 2D 1H NMR measurements. Detailed physiological
analysis of metabolic changes upon cold exposure will be
presented elsewhere.
The 13C (Figure 2A) and 1H (Figure 2B) spectra are plotted
in red (cold hardy) and blue (cold susceptible). As described
above, peak lists defining spin systems from the 13C−13C
STOCSY (Figure 2E) and 1H−13C-SHY (Figure 2F)
correlations were used to search the BMRB, which yielded
the 13 metabolites given in Supporting Information Table S1.
As above, the 13C data were more useful than 1H for database
matching. As an example, a slice of the 2D 13C−1H SHY with
13C driver peak 31.69 ppm (Figure 2D), which is the β carbon
of proline, shows correlations with many 1H resonances other
than the reference proline resonances (black), making
unambiguous proline identification using 1H alone difficult. In
contrast, the slice from the same (31.69 ppm) trace in the
13C−13C STOCSY (Figure 2C) showed very strong correla-
tions with all other proline peaks and matched those from the
BMRB perfectly. Metabolites such as glutamine and glutamate
could only be distinguished using the improved resolution and
chemical shift differences in 13C and not with the highly
overlapped 1H spectra. In the absence of 13C, many of these
metabolites would have been ambiguous using 1D 1H alone.
Prior to our study, methionine sulfoxide was not annotated in
the 1D or 2D 1H spectra of the fly metabolome and was found
here by statistically correlating carbons through heteroatoms
such as sulfur using 13C−13C STOCSY. Metabolites identified
in Supporting Information Table S1 were consistent with
previously collected and analyzed data using conventional
methods (Chenomx), 2D NMR, and spiking experiments
(Williams et al., unpublished results).
PLS-DA performed on the fly 13C 1D spectra yielded clear
separation of cold-hardy flies and cold-susceptible flies on
component 1 (Figure 3A). The 1H spectra failed to yield
separation on either component 1 or 2. Here we show that the
13C data provided much better separation between hardy and
susceptible flies (Q2 = 0.77 and R2 = 0.85) and had stronger
loadings than those from the 1H data in Figure 3B (Q2 = 0.24
and R2 = 0.34.). Annotated 13C and 1H loadings of component
1 are given in Figure 3. In addition, PCA performed on the fly
13C 1D spectra gave better separation along PC1 (Supporting
Information Figure S3A), while the 1H spectra gave some
separation along PC2 (Supporting Information Figure S3B).
The PC1 loadings for the 13C 1D spectra and PC2 loadings for
the 1H 1D spectra gave similar results as the PLS-DA. histidine,
AMP, phosphocholine, taurine, and methionine sulfoxide all
loaded with the hardy flies, and glucose (possibly also other
sugars), proline, alanine, and arginine loaded with the
susceptible flies. All of these compounds were identified and
verified as altered by selection in a parallel study using 1D and
2D 1H NMR, and the direction of alteration was confirmed in
78% of cases (all but AMP and taurine, which were higher in
susceptible flies in the parallel study: Williams et al.,
unpublished results). The differences in the direction of the
Figure 3. PLS-DA of 13C (A) and 1H (B) 1D spectra from cold hardy and cold susceptible flies. PLS-DA produced better separation of cold hardy
(red) and susceptible flies (blue) in 13C data with a Q2 value of 0.77 and an R2 value of 0.85 when compared to 1H data with a Q2 value of 0.24 and
an R2 value of 0.34. Loadings plots of component 1 for both 13C and 1H are given in (A) and (B) respectively. 13C component 1 loadings gave the
compounds contributing to the differences between the hardy and susceptible flies. 1H component 1 loadings plot (B) showed little differences
between the groups, though sugars seemed to load better with the cold susceptible flies. Red and positive peaks indicate resonances that were
correlated with cold hardy flies, and blue and negative resonances indicate resonances that correlated well with the cold susceptible. Annotations are
given for 1D 13C and 1H loadings plot (A and B, respectively).
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effect may be due to using only a subset of lines in the present
study, and the flies in the present study were also not exposed
to cold. These findings support the primary conclusions that
hardy flies have alterations to pathways involved in membrane
lipid metabolism, oxidative stress, and energy balance. These
alterations are consistent with the hypothesis that cold-hardy
flies maintain aerobic metabolism in the cold, preventing the
(potentially deleterious) accumulation of alanine and sugars.
13C NMR Offers Improved Confidence in Metabolite
Identification. The mdx mouse is an animal model for
Duchenne muscular dystrophy (DMD)a muscle degenerat-
ing disease found in young males. The inability to produce
dystrophin results in a pathology in mice similar to that seen in
humans.30 Tracking disease progression in children requires
difficult and painful muscle biopsies31 and effort-based
functional testing.32 Importantly, current methods may be
insensitive to therapeutic intervention. Identifying biomarkers
of disease progression for DMD using an easily obtained
sample such as serum or urine is essential for improving our
ability to treat and diagnose this debilitating disease.
Although the overall sensitivity with the small volume of
mouse serum prevents the detection of large numbers of
metabolites, we were able to obtain high-quality NMR data on
the most concentrated compounds, suggesting that 13C NMR
metabolomics using isotopically labeled compounds for flux
studies on survival bleeds is also possible with this probe.
Similar to the fly study, the mouse serum revealed that 13C
produced more robust PLS-DA results than 1H data, separating
along PC1 with a cross-validation (Q2) value of 0.67 and R2 of
0.79 compared to the 1H results of a Q2 value of 0.46 and R2
value of 0.66 (Supporting Information Figure S5). Thus, for at
least the two biological data sets analyzed in this paper, 13C
NMR data improves group separation using PLS-DA. Using the
13C workflow developed here, we have found that the addition
of 13C helps in making specific identifications and, perhaps
more important, in preventing the misidentification of
metabolites suggested by 1H NMR alone. For example, 1H
resonances at 0.9, 1.3, and 2.75 ppm are often associated with
fatty acids, but the specific fatty acid species is typically not
annotated. Here, with the addition of the 13C−13C STOCSY
and 13C−1H SHY correlation maps, we were able to identify
linoleic acid as the specific fatty acid abundant in our 1H and
13C spectra (Supporting Information Figure S4).
Figure 4 shows representative 1H and 13C 1D spectra from
the mouse serum. Previous NMR studies in the muscle of mdx
vs control mice have reported a decrease in muscle creatine that
varies with age and tissue, thought to result from increased
inflammation and degeneration of the muscle.33,34 It is
hypothesized that this leads to an in increase in serum creatine
of mdx mice through dystrophin deficient “leaky” muscle
membranes.34 In our data, the 1H PLS-DA results indicated a
resonance at 1.30 ppm that separates the control from mdx.
Analysis of the 1H STOCSY using 1.30 ppm as a driver peak
indicated a correlating resonance or overlapping resonances at
3.02 ppm, often assigned to creatine. However, other creatine
1H resonances were overlapped, making it difficult to analyze.
To further investigate whether creatine is associated with
disease development in the mdx mouse model, we examined
the 13C−1H SHY data and found correlations with the 3.02
ppm resonance to the 13C peaks at 56.5 and 41.2 ppm; the
correlation at 38.9 ppm we would expect to see for creatine was
not present (Figure 4). Creatine is often assumed to be the
largest contributor to the peak at 1H 3.02 ppm.35,36 To
determine if the absence of the creatine peak at 38.9 ppm in the
13C 1D was due to sensitivity limitations, we compared the
integrals of the 1H resonance at the 3.02 ppm (−CH3) to the
succinate at peak 2.39 ppm (CH2−CH2) (Figure 4A). Given
the relative abundance of the creatine compared to the
succinate resonance, we expect to see a 13C peak at 38.9 ppm
comparable to the succinate resonance seen at 36.5 ppm in the
13C spectra. Therefore, using 13C data we conclude that creatine
is not present at concentrations that we can measure in this
Figure 4. Analysis of specific resonances in mouse serum for metabolite identification or error detection. The mdx data are in red and the control in
blue. All the spectra are overlaid in (A), with the average data for each group shown as a bold line. Resonances at 3.02 ppm (unknown) and 2.39
ppm (succinate) in the 1H (A) are expanded, and the relative intensities are given in the box plot. Metabolites indicated in (B) are overlaid onto the
1D spectra (A and B). Expansion of the carbon 1D from ∼20 to 60 ppm shows the absence of creatine peak at 38.9 ppm, but the presence of a peak
at 36.5 ppm confirms the possibility of succinate. Using just the 1H data, the peak at 3.02 ppm would likely be assigned to creatine, which we can rule
out with the 13C data.
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experiment. This was verified by a spiking experiment with
synthetic creatine, which did not correspond to resonances
observed from the mice (data not shown). Despite extensive
precedent in the literature assigning 1H resonances at 3.02 ppm
in metabolomics mixtures, the 13C data clearly shows that
creatine would have been an incorrect assignment in our case.
Citrulline (Figure 4B) has a resonance near 3.02 ppm and is
another possible assignment of this peak. 13C−1H SHY and
13C−13C STOCSY data show correlations between the
resonance at 3.02 ppm in the 1H spectra and suspected
citrulline resonances 56.5 and 41.2 ppm. We do not, however,
observe strong correlations to other citrulline 13C peaks. In
addition, the 1H chemical shifts do not agree well with citrulline
(Figure 4A). Thus, by using both 1H and 13C spectra of the
same sample, we were able to rule out two previously associated
compounds as unlikely to be contributing to our NMR spectra.
Further analysis is needed to identify the compound(s)
associated with these peaks, but this result further demonstrates
the utility of 13C NMR in metabolomics studies.
Future Improvements. There are several possible
improvements that could be made in the future. First, a larger
volume NMR probe with 13C optimization would provide
greater absolute sensitivity. This, however, would result in
lower mass sensitivity because the sensitivity of NMR probes is
roughly inversely proportional to the diameter of the coils.37 A
5 mm NMR tube requires a volume that is approximately 600
μL compared with 40 μL for our 1.5 mm probe used here, a 15-
fold difference. A commercial 5 mm 13C optimized probe
would provide about 7-fold greater absolute sensitivity with 15-
fold more sample than our small volume probe.9 Therefore, for
situations that are not sample-limited such as human urine or
serum, a commercial large volume 13C probe would provide up
to about 7× better sensitivity than we can achieve using our
small volume probe. However, for mass-limited samples such as
mouse serum or D. melanogaster extracts, our 40 μL probe
would provide about 2× better results than the same quantity
of sample diluted to 600 μL. Second, a T1 relaxation agent
could be added to the samples to further reduce the relaxation
time and also better recover slowly relaxing quaternary carbons
that we attenuated in this study. Finally, dissolution dynamic
nuclear polarization (DNP) is an emerging technique that can
transiently enhance the 13C signal of a sample by >10 000 fold
for about 1 or 2 min.6 If some or all of these techniques could
be used to improve sensitivity of the NMR measurement even
more, then the benefits of 13C metabolomics that we have
demonstrated could be fully realized.
■ CONCLUSION
We have shown that by using a 13C-optimized NMR probe,9 we
were able to acquire high-quality 13C NMR data in a reasonable
amount of time and with relatively small sample volumes. The
overall workflow allowed for more accurate identification of
compounds through database matching by utilizing both the
standard 1D 13C and 1H NMR data. There is a cost of about 2
h per sample in terms of extra measurement time, but
inspection of the NMR spectra clearly shows the increased
spectral dispersion of the 13C compared to the 1H data from the
same sample (e.g., Figure 1A and B) that in turn leads to many
desirable results in database matching and ultimately better
separation of groups using multivariate analysis. Using the
synthetic mixture, we determined that the limit of analysis
through correlations was about 60 nmol, although this could be
improved even more with more sensitive NMR measurements.
When statistically combined with 1H NMR data on the same
samples, the 13C spectra enable new approaches that produce
the following: (1) peak lists for better spectral annotation, (2)
improved group separation using multivariate statistical analysis
because of reduced spectral overlap, and (3) improved
confidence in identified metabolites and the ability to reject
identifications based on 1H data alone. We developed and
validated our approach using a synthetic mixture and then
applied it to two different biological examples: D. melanogaster
cold tolerance models in which metabolites that significantly
changed between hardy and susceptible lines of flies were easily
identified and mass-limited mouse serum where metabolite
identification using 13C spectral analysis could not be done with
1H analysis alone. In the case of the mouse serum, the addition
of 13C data not only enhanced our ability to identify specific
compounds but it also prevented mistakes that could have been
made with 1H data alone.
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